广州中医药大学第二临床医学院的研究人员在Scientific Reports期刊上发表了题为 “Genomic epidemiology and phenotypic characterization of Staphylococcus aureus isolated from atopic dermatitis patients in South China” 的论文。该研究首次对中国特应性皮炎 ...

A recent study published in the Dermatology and Therapy journal confirmed the effectiveness and safety of upadacitinib, a ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

For children with atopic dermatitis (AD), early childhood stressful life events are associated with an increased risk for ...

Experiencing stressful life events in childhood was associated with an increased risk for active and severe atopic dermatitis ...

More information about the 2025 AAAAI / WAO Joint Congress can be accessed here.

杭州多域生物技术有限公司，成立于2018年，位于杭州市，是一家以从事研究和试验发展为主的企业。企业注册资本1104.8889万人民币，实缴资本671.6296万人民币。 主要股东信息显示，杭州多域生物技术有限公司由XIANG JASON SHAOYUN持股37.6937%、Matrix Partners China VI Hong Kong ...

Comment by Feb. 17 for your feedback to be reviewed by the guideline development workgroup.

An artificial intelligence (AI)-enabled hand sensor delivering closed-loop haptic feedback appeared to be an effective ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...